A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Exclusion Criteria

• •1. Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within 3 weeks before screening.
• •2. Has a history of any thrombotic or embolic event within 12 months before screening.
• •3. Has a history of splenectomy within 3 months before screening.
• •4. Use of intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin or anti-D immunoglobulin treatment within 4 weeks of screening, or an expectation that any therapy besides the participant's standard background therapies may be used for treatment of thrombocytopenia (e.g., a rescue therapy) between screening and dosing.
• •5. Diagnosed with chronic obstructive pulmonary disease (COPD) or asthma, and a prebronchodilatory forced expiratory volume in 1 second (FEV1) \<50% of predicted normal.
• •6. Use of rituximab or any monoclonal antibody (mAb) for immunomodulation within 4 months before first dosing. Note: Participants with prior exposure to rituximab must have cluster of differentiation (CD) 19 counts within the normal range at screening.
• •7. Use of immunosuppressants (such as cyclophosphamide, vincristine) other than permitted oral immunosuppressants within 6 months before first dosing.
• •8. Has been diagnosed with myelodysplastic syndrome.
• •9. Has received a live vaccine within 4 weeks before screening or has any live vaccine planned during the study.
• •10 Has had an opportunistic infection ≤12 weeks before initial study dosing or is currently undergoing treatment for a chronic opportunistic infection, such as tuberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.